Pharmacodynamics of combined estrogen–progestin oral contraceptives: 4. Effects on uterine and cervical epithelia

References

• Bastianelli C, Farris M, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017;10:315–326.
   PubMed Web of Science ®Google Scholar
• Farris M, Bastianelli C, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10:1129–1144.
   PubMed Web of Science ®Google Scholar
• Bastianelli C, Farris M, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation. Expert Rev Clin Pharmacol. 2018;11:1085–1098.
   PubMed Web of Science ®Google Scholar
• Gondos B. Histologic changes associated with oral contraceptive usage. Ann Clin Lab Sci. 1976;6:291–299.
   PubMedGoogle Scholar
• Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013;22:1931–1943.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant metaanalysis of 27.276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061–1070.
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1-580.e9.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Wise MR, Weterings MAJ, et al. Combined hormonal contraceptives for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;2(2):CD000154.
   Web of Science ®Google Scholar
• Wang Y, Nisenblat V, Tao L, et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol. 2019;30:e49.
   PubMed Web of Science ®Google Scholar
• La Vecchia C, Boccia S. Oral contraceptives, human papillomavirus and cervicalcancer. Eur J Cancer Prev. 2014;23:110–112.
   PubMed Web of Science ®Google Scholar
• Xu H, Egger S, Velentzis LS, et al. Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: a case-control study in New South Wales, Australia. Cancer Epidemiol. 2018;55:162–169.
   PubMed Web of Science ®Google Scholar
• Monds RE. Pseudomalignant endometrial changes induced by administration of new synthetic progestins. Proc Mayo Clin. 1959;34:321–328.
   PubMed Web of Science ®Google Scholar
• Martinez-Manautou J, Maqueo M, Gilbert RA, et al. Human endometrial activity of several new derivatives of 17-acetoxyprogesterone. Fertil Steril. 1962;13:169–183.
   PubMed Web of Science ®Google Scholar
• Maqueo M, Perez-Vega E, Goldzieher JW, et al. Comparison of the endometrial activity of 3 synthetic progestins used infertility control. Amer J Obstet Gynecol. 1963;85:427–432.
   PubMed Web of Science ®Google Scholar
• Rice-Wray E, Arando-Rosell A, Maqueo M, et al. Comparison of the long-term endometrial effects of synthetic progestins used in fertility control. Amer J Obstet Gynecol. 1963;87:429–433.
   PubMed Web of Science ®Google Scholar
• Roland M, Clyman MJ, Decker A, et al. Sequential endometrial alterations during one cycle of treatment with synthetic progestagen-estrogen compounds. Fertil Steril. 1966;17:338–350.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Maqueo M, Chenault CB, et al. Comparative studies of the ethynyl estrogens used in oral contraceptives. I. Endometrial response. Am J Obstet Gynecol. 1975;122:615–618.
   PubMed Web of Science ®Google Scholar
• ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod. 2001;16:1527–1535.
   PubMed Web of Science ®Google Scholar
• Dinh A, Sriprasert I, Williams AR, et al. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception. 2015;91:360–367.
   PubMed Web of Science ®Google Scholar
• Clyman MJ. Electron microscopic changes produced in the human endometrium by norethindrone acetate with ethinyl estradiol. Fertil Steril. 1963;14:352–364.
   PubMed Web of Science ®Google Scholar
• Ryan GM, Craig J, Reid DE. Histology of the uterus and ovaries after long-term cyclic norethynodrel therapy. Am J Obstet Gynecol. 1964;90:715–725.
   PubMed Web of Science ®Google Scholar
• Ober WB. Synthetic progestagen-oestrogen preparations and endometrial morphology. J Clin Pathol. 1966;19:138–147.
   PubMed Web of Science ®Google Scholar
• Utsumi K, Kuribayashi N, Kumakiri S. Endometrial changes induced by the administration of an oral contraceptive, norethindrone (S-3800B) PatholInternat. Acta Pathologica Japonica. 1966;16:141–150.
   PubMedGoogle Scholar
• Lévrier M, Delmon G. Action des estro-progéstatifs sur l’endomètre] [Action of estroprogestatives on the endometrium. Histochemical study]. Bull Fed SocGynecol Obstet Lang Fr. 1971;23:157–158.
   PubMedGoogle Scholar
• Dollar JR, Boots LR, Santolucito KA, et al. Morphological and histochemical study of the endometrial effects of Ovral in the baboon. Cell Tissue Res. 1981;217:611–624.
   PubMed Web of Science ®Google Scholar
• Nayel SA, Gawad AA, Sibai FA, et al. Scanning electron microscopy of the human endometrium in pill users. Asia-Oceania J Obstet Gynaecol. 1987;13:211–214.
   PubMedGoogle Scholar
• Wynn RM, Sawaragi I. Effects of intrauterine and oral contraceptives on the ultrastructure of the human endometrium. J Reprod Fertil. 1969;8(Suppl. 8):45.
   Google Scholar
• Gonzalez-Gómez F, Merchan J, Caballero-Peregrin P, et al. Aspectos electromicroscopicos de la distrofia endometrial producida poranticonceptivos orales [Electronmicroscopic aspects of endometrial dystrophy induced by oral contraceptives]. Reproduccion. 1975;2:233–245.
   PubMedGoogle Scholar
• Rabe T, Leppien G, Kiesel L, et al. Licht- und elektronen-mikroskopische veranderungen des endometriums untereinnahme eines norgestimathaltigen oralen kontrazeptivums (CILEST®) [Light and electron microscopy changes in the endometrium caused by the administration of a norgestimate-containing oral contraceptive (Cilest)]. Geburtshilfe Frauenheilkd. 1986;46:883–891.
   PubMedGoogle Scholar
• Csermely T, Hughes EC, Demers LM. Effect of oral contraceptives on human endometrium in culture. Am J Obstet Gynecol. 1971;109:1066–1072.
   PubMed Web of Science ®Google Scholar
• Shearman RP. Amenorrhea after treatment with oral contraceptives. Lancet. 1966;2:1110.
   PubMed Web of Science ®Google Scholar
• Maqueo M, Rice-Wray E, Gorodovsky J, et al. Endometrial regeneration in patients discontinuing oral contraceptives. Fertil Steril. 1970;21:224–229.
   PubMed Web of Science ®Google Scholar
• De Brux J, Tiburce P, Borghetti Ancla M. La regénération de l’endomètre après cessation des traitements oestro progestatifs combinés [The endometrialregeneration after cessation of combined estrogenic and progestative treatments]. Gynécologie. 1973;24:163–168.
   PubMedGoogle Scholar
• Hull MGR, Bromham DR, Savage PH, et al. Post-pill amenorrhea: a causal study. Fertil Steril. 1981;386:472–476.
   Google Scholar
• Bernardini L, Araujo FE, Balmaceda JP. A case of permanent endometrial hypotrophy after long-term use of oral contraceptives. Hum Reprod. 1993;8:543–546.
   PubMed Web of Science ®Google Scholar
• Dallenbach-Hellweg G. Exogenous (iatrogenic) changes of the endometrium. In: Dallenbach-Hellweg G, editor. Histopathology of the Endometrium. Berlin: Springer-Verlag; 1981. p. 158–177.
   Google Scholar
• Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception. 1997;56:23–30.
   PubMed Web of Science ®Google Scholar
• Mitra PK, Roychadhuri J. Effect of oral contraceptives on the ultrastructure of the endometrium. J Gynaecol Endocrinol. 1987;3:13–15.
   PubMedGoogle Scholar
• Nahmanovici C, De Brux J, Audebert A, et al. Etude de la maturation de l’endomètre sous l’influence d’un estro-progestatifcontenant 30 mcg d’EE et 150 mcg de desogestrel: intérêt de la biopsie del’endomètre pour evaluer l’efficacité d’un estro-progestatif [Study of endometrial maturation under the influence of an oestrogen-progestin combination containing 30 mcg of EE and 150 MCG of desogestrel: the value of biopsy of the endometrium in assessing the efficacy of an oestrogen-progestin combination]. Contracept Fertil Sexual. 1988;16:305–308.
   Google Scholar
• Archer DF. Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval. Contraception. 1999;60:151–154.
   PubMed Web of Science ®Google Scholar
• Coenen CMH, Hollanders JMG, Rolland R, et al. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women. Eur J Contracept Reprod Health Care. 1996;1:325–329.
   PubMedGoogle Scholar
• Oosterbaan HP. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women. Eur J Contracept Reprod Health Care. 1999;4(Suppl2):3–8.
   PubMedGoogle Scholar
• Lüdicke F, Johannisson E, Helmerhorst FM, et al. Effect of a combined oral contraceptive containing 3 mg of drospirenone and30 µg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76:02–7.
   Web of Science ®Google Scholar
• Rabe T, Johanisson E. The influence of ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg on the thickness and histology of the endometrium. J Appl Ther Res. 2008;6:3–10.
   Google Scholar
• Rabe T, Hartschuh E, Wahlstrom T, et al. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles. Contraception. 2010;82:358–365.
   PubMed Web of Science ®Google Scholar
• Klebe U, Moltz L, Pickartz H. Effects of cyproterone acetate and ethinylestradiol on endometrial histology. Arch Gynecol. 1983;234:113–120.
   PubMedGoogle Scholar
• Fedele L, Cavalli G, Marchini M, et al. Effect of a new oral antiandrogen-estrogen combination on the endometrium: histological and ultrastructural scanning electron microscopy study. Acta Eur Fertil. 1986;17:9–13.
   PubMedGoogle Scholar
• Anderson FD, Hait H, Hsiu J, et al. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception. 2005;71:55–59.
   PubMed Web of Science ®Google Scholar
• Anderson FD, Feldman R, Reape KZ. Endometrial effects of a 91-day extended regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception. 2008;77:91–96.
   PubMed Web of Science ®Google Scholar
• Brosens IA, Robertson WB, Van Assche FA. Assessment of incremental dosage regimen of combined oestrogen-progestogen oral contraceptive. Br Med J. 1974;4(5945):643–645.
   PubMedGoogle Scholar
• Brosens I, Van Assche A, Koninckx PH, et al. New combined oral contraceptive with incremental progestogen dosage regimen. Eur J Obstet Gynecol Reprod Biol. 1976;6:315–318.
   PubMed Web of Science ®Google Scholar
• Khoo SK, McKenna H. An incremental-dose combined oestrogen-progestogen oral contraceptive: cycle control and endometrial changes. Aust N Z J Obstet Gynecol. 1980;20:168–171.
   PubMed Web of Science ®Google Scholar
• Farkas M, Farkas E, Sas M. Examination of the effect of Anteovin (EE+LNG)tablet on the endometrium. Ther Hung. 1985;33:71–78.
   PubMedGoogle Scholar
• Brosens I. Vaginal, cervical and endometrial changes during the triphasic pill. In: Haspels AA, Rolland R, editors. Benefits and risks of hormonal contraception. Has the attitude changed? Dordrecht (Germany): Springer; 1982. p. 135–142.
   Google Scholar
• Wynants P, Ide P. Endometrial morphology during a normophasic and a triphasic regimen (EE+LNG): a comparison. Contraception. 1986;33:149–157.
   PubMed Web of Science ®Google Scholar
• Rabe T, Nitsche DC, Runnebaum B. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reprod Health Care. 1997;2:39–51.
   PubMedGoogle Scholar
• Bitzer J, Parke S, Roemer T, et al. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J WomensHealth. 2011;18(3):127–132.
   Google Scholar
• Koninckx PR, Lauweryns JM, Cornillie FJ. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation. Maturitas. 1993;16:97–110.
   PubMed Web of Science ®Google Scholar
• Umapathysivam K, Jones WR. Effects of contraceptive agents on the biochemical and protein composition of human endometrium. Contraception. 1980;22:425–440.
   PubMed Web of Science ®Google Scholar
• Carol W, Jäger R, Martin P, et al. Das verhalten der zytoplasmatischenprogesteronrezeptoren im zyklischen endometrium und unter der einwirkunghormonaler kontrazeptiva [The behavior of cytoplasmic progesterone receptors in the cycling endometrium and the effect of hormonal contraceptives]. Zentralbl Gynakol. 1989;111:793–799.
   PubMedGoogle Scholar
• Rubin GL, Harrold AJ, Mills JA, et al. Regulation ofsulphotransferase expression in the endometrium during the menstrual cycle,by oral contraceptives and during early pregnancy. Mol Hum Reprod. 1999;5:995–1002.
   PubMed Web of Science ®Google Scholar
• Casals G, Ordi J, Creus M, et al. Osteopontin and alpha-beta3 integrin as markers of endometrial receptivity: the effect of different hormone therapies. Reprod Biomed Online. 2010;21:349–359.
   PubMed Web of Science ®Google Scholar
• Maia H, Casoy J, Correia T, et al. The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis. Gynecol Endocrinol. 2008;24:123–128.
   PubMed Web of Science ®Google Scholar
• Galant C, Berlière M, Dubois D, et al. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol. 2004;165:83–94.
   PubMed Web of Science ®Google Scholar
• Prifti S, Lelle I, Zhong G, et al. Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Gynecol Endocrinol. 2004;18:23–27.
   PubMed Web of Science ®Google Scholar
• Vincent AJ, Zhang J, Ostor A, et al. Metalloproteinase-1 and −3 and mast cells are present in the endometrium of women using progestin-only contraceptives. Hum Reprod. 2000;15:123–130.
   PubMed Web of Science ®Google Scholar
• Kaneshiro B, Edelman A, Dash C, et al. Effect of oral contraceptives and doxycycline on endometrial MMP-2 and MMP-9 activity. Contraception. 2016;93:65–69.
   PubMed Web of Science ®Google Scholar
• Kaneshiro B, Edelman A, Carlson N, et al. Treatment of unscheduled bleeding in continuous oral contraceptive users with doxycycline: a randomized controlled trial. Obstet Gynecol. 2010;115:1141–1149.
   PubMed Web of Science ®Google Scholar
• Kaneshiro B, Edelman A, Carlson NE, et al. A randomized controlled trial of subantimicrobial dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012;85:351–358.
   PubMed Web of Science ®Google Scholar
• Fleming DC, King AE, Williams AR, et al. Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril. 2003;79:856–863.
   PubMed Web of Science ®Google Scholar
• Talukdar N, Bentov Y, Chang PT, et al. Effect of long-term combined oral contraceptive pill use on endometrial thickness. Obstet Gynecol. 2012;120(2 Pt 1):348–354.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet Oncol. 2015;16:1061–1070.
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1-580.e9.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Becerra C, Gual C, et al. New oral contraceptive: sequential estrogen and progestin. Am J Obstet Gynecol. 1964;90:404–441.
   PubMed Web of Science ®Google Scholar
• Maqueo M, Becerra C, Munguia H, et al. Endometrial histology andvaginal cytology during oral contraception with sequential estrogen and progestin. Am J Obstet Gynecol. 1964;90:395–400.
   PubMed Web of Science ®Google Scholar
• Ober WB, Decker A, Clyman MJ, et al. Endometrial morphology after sequential medication with mestranol and chlormadinone. Obstet Gynecol. 1966;28:247–253.
   PubMed Web of Science ®Google Scholar
• Kaltenbaeh FJ, Fettig O, Welter J. Histologische und autoradiographische Untersuchungen am menschlichen Endometrium unter der 2-Phasen-Therapiecmit Mestranol – lynestrenol [Histological and autoradiographic investigations on the human endometrium under the 2-phase therapy with mestranollynestrenol].Arch. Gynäkol. 1973;215:325–342.
   Google Scholar
• Kreutner A, Johnson D, Williamson O. Histology of the endometrium in longterm use of a sequential oral contraceptive. Fertil Steril. 1976;27:905–910.
   PubMed Web of Science ®Google Scholar
• Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med. 1976;294:1259–1262.
   PubMed Web of Science ®Google Scholar
• Cortés-Gallegos V, Carranco A, Sojo I, et al. Accumulation of ethinylestradiol in blood and endometrium of women taking oral contraceptives: the sequential therapy. Fertil Steril. 1979;32:524–527.
   PubMed Web of Science ®Google Scholar
• Coppens M, Thiery M. Endometrial response to the use of a sequential oral contraceptive. J Obstet Gynaecol. 1988;8:281–284.
   Google Scholar
• Dombrowicz N, Van de Walle J. Combined clinical, histological and stereomorphometric studies with a new oral contraceptive of normophasic type: fysioquens. Contraception. 1980;22:537–548.
   PubMed Web of Science ®Google Scholar
• Boyce JG, Lu T, Nelson JH, et al. Oral contraceptives and cervicalcarcinoma. Am J Obstet Gynecol. 1977;128:761–766.
   PubMedGoogle Scholar
• Melamed MR, Koss LG, Flehinger BJ, et al. Prevalence rates of uterine cervical carcinoma in situ for women using the diaphragm or contraceptive oral steroids. Br Med J. 1969;3:195–200.
   PubMed Web of Science ®Google Scholar
• Brinton LA. Oral contraceptives and cervical neoplasia. Contraception. 1991;43:581–595.
   PubMed Web of Science ®Google Scholar
• Konishi I, Fujii S, Nonogaki H, et al. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer. 1991;68:1340–1350.
   PubMed Web of Science ®Google Scholar
• Green J, Berrington de Gonzalez A, Smith JS, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer. 2003;88:1713–1720.
   PubMed Web of Science ®Google Scholar
• Moreno V, Bosch FX, Muñoz N, et al. International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–1092.
   PubMed Web of Science ®Google Scholar
• Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159–1167.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370(9599):1609–1621.
   PubMed Web of Science ®Google Scholar
• Peng Y, Wang X, Feng H, et al. Is oral contraceptive use associated with an increased risk of cervical cancer? An evidence-based meta-analysis. J Obstet Gynaecol Res. 2017;43:913–922.
   PubMed Web of Science ®Google Scholar
• Adhikari I, Eriksson T, Luostarinen T, et al. The risk of cervical atypia in oral contraceptive users. Eur J Contracept Reprod Health Care. 2018;23:12–17.
   PubMed Web of Science ®Google Scholar
• Taylor HB, Irey NS, Norris HJ. Atypical endocervical hyperplasia in women taking oral contraceptives. JAMA. 1967;202:636–639.
   Web of Science ®Google Scholar
• Kyriakos M, Kempson RL, Konikov NF. A clinical and pathologic study of endocervical lesions associated with oral contraceptives. Cancer. 1968;22:99–110.
   PubMed Web of Science ®Google Scholar
• Gall SA, Bourgeois CH, Maguire R. The morphologic effects of oral contraceptive agents on the cervix. JAMA. 1969;207:2243–2247.
   PubMed Web of Science ®Google Scholar
• Govan ADT, Black WP, Sharp JL. Aberrant glandular polypi of the uterine cervix associated with contraceptive pills. Pathology and pathogenesis. J Clin Pathol. 1969;22:84–89.
   PubMed Web of Science ®Google Scholar
• Carbia E, Rubio-Linares G, Alvarado-Duran A, et al. Histologic study of the uterine cervix during oral contraception with ethynodiol diacetate and mestranol. Obstet Gynecol. 1970;35:381–388.
   PubMed Web of Science ®Google Scholar
• Stern E, Clark VA, Coffelt CF. Contraceptives and dysplasia: higher rates for pillchoosers. Science. 1970;269:497–498.
   Google Scholar
• De Brux J. Oestro-progestatifs oraux et col uterin. Path Europ. 1972;7:283.
   PubMedGoogle Scholar
• Thomas DB. Relationship of oral contraceptives to cervical carcinogenesis. Obstet Gynecol. 1972;40:508–518.
   PubMed Web of Science ®Google Scholar
• Melamed MR, Flehinger BJ. Early incidence rates of precancerous cervical lesions in women using contraceptives. Gynecol Oncol. 1973;1:290–298.
   Google Scholar
• Lindenbaum J, Whitehead N, Reyner F. Oral contraceptive hormones, folate metabolism, and the cervical epithelium. Am J Clin Nutr. 1975;28:346–353.
   PubMed Web of Science ®Google Scholar
• Werner R, Dinges HP. Uber durch ovulationshemmer verursachte spezifischeveranderungen der cervix uteri [Specific changes of the uterine cervix due to contraceptives]. Zentralbl Gynakol. 1976;98:919–926.
   PubMedGoogle Scholar
• Ober WB. Effects of oral and intrauterine administration of contraceptives on the uterus. Hum Pathol. 1977;8:513–527.
   PubMed Web of Science ®Google Scholar
• Clark MK, Kennedy Stockdale C, Railsback L, et al. Differences in cervical cytologic and histologic findings between women using depot-medroxyprogesterone acetate and oral contraceptives. J Low Genit Tract Dis. 2011;15:219–223.
   PubMed Web of Science ®Google Scholar
• Milam MR, Pollock JW, Nick AM, et al. The effect of hormonal contraception on the adequacy of colposcopic examination of the cervix. Am J Obstet Gynecol. 2005;192:1368–1369.
   PubMed Web of Science ®Google Scholar
• Clarke EA, Hatcher J, McKeown-Eyssen GE, et al. Cervical dysplasia: association with sexual behavior, smoking, and oral contraceptive use? Am J Obstet Gynecol. 1985;151:612–616.
   PubMed Web of Science ®Google Scholar
• Singh EJ, Swartwout JR. Human cervical mucus lipids. A preliminary report. J Reprod Med. 1972;8:35–40.
   PubMed Web of Science ®Google Scholar
• Singh EJ, Swartwout JR. Effects of oral contraceptives on glycerides and sterol esters of human cervical mucus. Am J Obstet Gynecol. 1972;114:484–491.
   PubMed Web of Science ®Google Scholar
• Singh EJ. Oral contraceptives and human cervical mucus lipids. Am J Obstet Gynecol. 1975;123:128–132.
   PubMed Web of Science ®Google Scholar
• Wolf DP, Blasco L, Khan MA, et al. Human cervical mucus. v. oral contraceptives and mucus rheologic properties. Fertil Steril. 1979;32:166–169.
   PubMed Web of Science ®Google Scholar
• Elstein M, Morris SE, Groom GV, et al. Studies on low-dose oral contraceptives: cervical mucus and plasma hormone changes in relation to circulating d-norgestrel and 17a-ethynyl estradiol concentrations. Fertil Steril. 1976;27:892–899.
   PubMed Web of Science ®Google Scholar
• Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol. 1999;42:93–106.
   PubMed Web of Science ®Google Scholar
• Steward R, Melamed A, Granat A, et al. Comparison of cervical mucus of 24/4 vs. 21/7 combined oral contraceptives. Contraception. 2012;86:710–715.
   PubMed Web of Science ®Google Scholar
• Aksoy M, Guven S, Tosun I, et al. The effect of ethinyl estradiol and drospirenone-containing oral contraceptives upon mucoprotein content of cervical mucus. Eur J Obstet Gynecol Reprod Biol. 2012;64:40–43.
   Google Scholar